HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antibody-based vaccines for the treatment of melanoma.

Abstract
Malignant melanoma remains a difficult clinical problem. Chemotherapy is not effective and immunotherapy has long been contemplated as the preferred approach to this disease. Extensive passive and active immunotherapy trials have been conducted. Active vaccination with whole cells or defined antigens, administered with a panoply of techniques to increase immunogenicity, has yielded inconsistent results. The development of antibody-based vaccines has allowed vaccination without the need for tumor tissue material or purified antigens. The idiotype network theory originally proposed by Lindemann and by Jerne provided the basis for the development of anti-idiotype (anti-Id) antibody vaccines, which mimic the internal image of the epitope targeted for immunization. Preclinical and phase I clinical data are available for various malignancies. In melanoma, some of the anti-Id vaccines have targeted gangliosides. One of these vaccines, TriGem, has been successful in generating a robust and specific humoral immunity in melanoma patients. Phase II data suggest this anti-Id vaccine has clinical activity.
AuthorsJose Lutzky, Ana M Gonzalez-Angulo, Jennifer A Orzano
JournalSeminars in oncology (Semin Oncol) Vol. 29 Issue 5 Pg. 462-70 (Oct 2002) ISSN: 0093-7754 [Print] United States
PMID12407511 (Publication Type: Journal Article, Review)
CopyrightCopyright 2002, Elsevier Science (USA). All rights reserved.
Chemical References
  • Antibodies, Anti-Idiotypic
  • Antigens, Neoplasm
  • Cancer Vaccines
Topics
  • Animals
  • Antibodies, Anti-Idiotypic (immunology)
  • Antibody Formation
  • Antigens, Neoplasm (immunology)
  • Cancer Vaccines (immunology, therapeutic use)
  • Humans
  • Melanoma (immunology, secondary, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: